The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2.
Edward Wolin
Consultant or Advisory Role - Novartis
Nicola Fazio
Honoraria - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Robert Winkler
Employment or Leadership Position - Novartis
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Larry Kvols
Consultant or Advisory Role - Novartis
Honoraria - Novartis